IN2012DN00624A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00624A
IN2012DN00624A IN624DEN2012A IN2012DN00624A IN 2012DN00624 A IN2012DN00624 A IN 2012DN00624A IN 624DEN2012 A IN624DEN2012 A IN 624DEN2012A IN 2012DN00624 A IN2012DN00624 A IN 2012DN00624A
Authority
IN
India
Prior art keywords
fatigue
treatments
diseases
prevention
compositions
Prior art date
Application number
Inventor
Moise A Khayrallah
Gary Bream
Stephen E Butts
Susan Marie Melnick
Duncan Taylor
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of IN2012DN00624A publication Critical patent/IN2012DN00624A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the compounds and compositions of the invention and use thereof for treatment and/or prevention of fatigue, including fatigue associated with diseases or treatments. Figure 1A
IN624DEN2012 2009-06-22 2010-06-21 IN2012DN00624A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21908209P 2009-06-22 2009-06-22
PCT/US2010/039313 WO2011005473A2 (en) 2009-06-22 2010-06-21 Methods for treating or preventing fatigue

Publications (1)

Publication Number Publication Date
IN2012DN00624A true IN2012DN00624A (en) 2015-06-12

Family

ID=43429751

Family Applications (1)

Application Number Title Priority Date Filing Date
IN624DEN2012 IN2012DN00624A (en) 2009-06-22 2010-06-21

Country Status (12)

Country Link
US (5) US8741950B2 (en)
EP (1) EP2445490B1 (en)
JP (3) JP6095366B2 (en)
KR (3) KR20120098578A (en)
CN (2) CN102481274A (en)
AU (1) AU2010270971B2 (en)
BR (1) BRPI1015233A2 (en)
IN (1) IN2012DN00624A (en)
MX (1) MX2012000034A (en)
RU (1) RU2567801C2 (en)
TW (1) TWI453014B (en)
WO (1) WO2011005473A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1890684B1 (en) 2005-06-08 2013-08-14 SK Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
KR20120098578A (en) 2009-06-22 2012-09-05 에스케이바이오팜 주식회사 Methods for treating or preventing fatigue
EP2496227B1 (en) * 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
BR112012010670A2 (en) 2009-11-06 2016-04-12 Sk Biopharmaceuticals Co Ltd Methods for Treatment of Attention Deficit / Hyperactivity Disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US9060994B2 (en) 2011-12-21 2015-06-23 Inno Biosciences, S.p.A. Combination therapy with interferon and andrographolides for Multiple Sclerosis
CA2905457A1 (en) * 2013-03-13 2014-10-09 Aerial Biopharma, Llc Treatment of cataplexy
JP2016530240A (en) * 2013-07-12 2016-09-29 ジャズ ファーマスティカルズ インターナショナル スリー リミテッドJazz Pharmaceuticals International Iii Limited Promotion of smoking cessation
CA2917702A1 (en) 2013-07-18 2015-01-22 Jazz Pharmaceuticals International Iii Limited Treatment for obesity
JP6742904B2 (en) * 2013-11-08 2020-08-19 レガシー ヘルスケア リミテッド Compositions for use in the treatment of cancer and co-morbidities of cancer
TWI698415B (en) 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 Aminocarbonylcarbamate compounds
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
MY197630A (en) 2016-09-06 2023-06-29 Sk Biopharmaceuticals Co Ltd Solvate form of (r)-2-amino-3-phenylpropyl carbamate
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
ES2964943T3 (en) 2016-10-06 2024-04-10 Axsome Malta Ltd Carbamoylphenylalaninol compounds for medical use
JP2020514465A (en) * 2016-12-30 2020-05-21 ドンジン セミケム カンパニー リミテッドDongjin Semichem Co., Ltd. Coating composition and film produced therefrom
BR112019025286A2 (en) 2017-06-02 2020-06-23 Jazz Pharmaceuticals Ireland Limited METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPING
JP7366002B2 (en) 2017-07-31 2023-10-20 ジャズ ファーマシューティカルズ アイルランド リミテッド Carbamoylphenylalaninol analogs and their uses
JP7428480B2 (en) * 2019-06-06 2024-02-06 雪印メグミルク株式会社 Compositions for improving sleep and foods, medicines, and feed containing the compositions
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR102390194B1 (en) 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 A composition for treating Kca3.1 channel mediated diseases comprising phenylalkyl carbamate compounds
US20250032442A1 (en) * 2021-11-16 2025-01-30 Axsome Malta Ltd. Methods and compositions for treating cognitive impairment
KR20260033050A (en) 2023-06-29 2026-03-10 액섬 테라퓨틱스, 인크. How to administer solriamfetol to lactating women

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ260667A (en) 1993-06-10 1997-05-26 Lilly Co Eli Preventing emesis or treating sexual dysfunction using tetrahydrobenz[cd]indole 6-carboxamides
KR100197892B1 (en) 1994-09-09 1999-06-15 남창우 Novel phenylalkylaminoalcohol carbamates and process for preparing the same
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (en) 1995-02-11 1999-04-01 조규향 O-carbamoyl- (D) -phenylalaninol compounds and their pharmaceutically useful salts and methods for their preparation
KR0173863B1 (en) * 1995-04-10 1999-04-01 조규향 O-carbamoyl-phenylalanineol compounds having substituents on phenyl, pharmaceutically useful salts thereof, and preparation methods thereof
WO1998015626A2 (en) 1996-10-08 1998-04-16 Institute Of Child Health Mutant ciita molecule and uses thereof
DK0873308T3 (en) 1996-10-10 2002-04-22 Sk Corp O-Carbamoyl-phenylalaninol compounds and their pharmaceutically useful salts
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
US20040229951A1 (en) 2003-05-15 2004-11-18 Arthur Vanmoor Method of treating fatigue by enhancing the effectiveness of the human immune system
RU2267319C2 (en) * 2003-07-15 2006-01-10 Общество с ограниченной ответственностью "Интер-Кэр" Pharmaceutical composition and method for treating chronic fatigue syndrome due to its application
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
RU2007119648A (en) * 2004-10-28 2008-12-10 СК Холдингз Ко. METHOD FOR TREATING DEPRESSION
EP1890684B1 (en) * 2005-06-08 2013-08-14 SK Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
ES2344469T3 (en) 2005-06-22 2010-08-27 Sk Holdings Co., Ltd. SEXUAL DYSFUNCTION TREATMENT.
ES2385087T3 (en) 2005-07-26 2012-07-18 Sk Biopharmaceuticals Co., Ltd Procedures for treating substance-related disorders
BRPI0719275A2 (en) 2006-10-13 2014-04-29 Janssen Pharmaceutica Nv PHENYL-ALKYL-AMINO CARBAMATE COMPOSITIONS
KR20120098578A (en) * 2009-06-22 2012-09-05 에스케이바이오팜 주식회사 Methods for treating or preventing fatigue
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
EP2496227B1 (en) 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
BR112012010670A2 (en) 2009-11-06 2016-04-12 Sk Biopharmaceuticals Co Ltd Methods for Treatment of Attention Deficit / Hyperactivity Disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
CA2905457A1 (en) * 2013-03-13 2014-10-09 Aerial Biopharma, Llc Treatment of cataplexy
JP6215740B2 (en) * 2014-03-14 2017-10-18 本田技研工業株式会社 Part fastening structure

Also Published As

Publication number Publication date
US20170000756A1 (en) 2017-01-05
CN106727486A (en) 2017-05-31
JP6095366B2 (en) 2017-03-15
JP6368285B2 (en) 2018-08-01
AU2010270971A1 (en) 2012-01-19
MX2012000034A (en) 2012-02-21
KR102021075B1 (en) 2019-11-04
CA2765463A1 (en) 2011-01-13
TW201105320A (en) 2011-02-16
EP2445490B1 (en) 2023-02-08
KR20120098578A (en) 2012-09-05
WO2011005473A2 (en) 2011-01-13
US20200061017A1 (en) 2020-02-27
KR102173587B1 (en) 2020-11-04
US9464041B2 (en) 2016-10-11
BRPI1015233A2 (en) 2018-02-20
US20140243406A1 (en) 2014-08-28
JP2015214564A (en) 2015-12-03
RU2012101947A (en) 2013-07-27
TWI453014B (en) 2014-09-21
JP2018188450A (en) 2018-11-29
US9999609B2 (en) 2018-06-19
KR20190105675A (en) 2019-09-17
US8741950B2 (en) 2014-06-03
CN102481274A (en) 2012-05-30
US10507192B2 (en) 2019-12-17
US20120142769A1 (en) 2012-06-07
AU2010270971B2 (en) 2015-08-20
KR20170086710A (en) 2017-07-26
JP2012530779A (en) 2012-12-06
EP2445490A4 (en) 2019-10-23
RU2567801C2 (en) 2015-11-10
EP2445490A2 (en) 2012-05-02
US20180263950A1 (en) 2018-09-20
CA2765463C (en) 2018-10-09
WO2011005473A9 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
IN2012DN00624A (en)
IN2012DN03883A (en)
MX351464B (en) Methods for the treatment of allergic diseases.
MX2018009945A (en) Novel compositions and methods for the treatment of immune related diseases.
MY172372A (en) Compositions and methods for lowering triglycerides
MX2011009539A (en) Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof.
NZ727304A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
EP2294184A4 (en) Treatment of eye diseases and excessive neovascularization using a combined therapy
MX2011007930A (en) Crystalline insulin-conjugates.
MY161495A (en) Virus like particle compositions and methods of use
IN2012DN02471A (en)
IN2012DN02081A (en)
AU2011338383A8 (en) Treatment of HER2-positive cancer with paclitaxel and trastuzumab-MCC-DM1
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
MX2009013353A (en) Telomerase activating compounds and methods of use thereof.
MX343135B (en) Fumagillol type compounds and methods of making and using same.
MY178905A (en) Prevention, treatment and diagnosis of p.gingivalis infection
TN2011000482A1 (en) Organic compounds and their uses
MX2009009761A (en) Compositions and kits for treating influenza.
UA107204C2 (en) ANTI-FUNCTIONAL COMPOSITION CONTAINING THE PYTHIUM OLIGANDRUM Fungal Organism
TNSN08400A1 (en) Organic compounds and their uses
MX342947B (en) Treatment of type 2 diabetes.
WO2013098416A3 (en) Pain relief compounds
EP2585067A4 (en) Compound for the treatment of enteroviruses
MY150931A (en) Substituted oxazolidinones and their use